StockNews.com Downgrades Can-Fite BioPharma (NYSE:CANF) to Sell

Posted by Paula Ricardo on Nov 3rd, 2024

StockNews.com downgraded shares of Can-Fite BioPharma (NYSE:CANF – Free Report) from a hold rating to a sell rating in a research report released on Wednesday.

Separately, EF Hutton Acquisition Co. I upgraded shares of Can-Fite BioPharma to a “strong-buy” rating in a report on Wednesday, July 17th.

Check Out Our Latest Research Report on Can-Fite BioPharma

Can-Fite BioPharma Stock Up 0.5 %

NYSE CANF opened at $2.16 on Wednesday. Can-Fite BioPharma has a 12-month low of $1.83 and a 12-month high of $4.69. The company has a market capitalization of $7.65 million, a PE ratio of -1.21 and a beta of 1.41. The firm’s 50 day moving average is $2.28 and its 200-day moving average is $2.51.

Hedge Funds Weigh In On Can-Fite BioPharma

A hedge fund recently raised its stake in Can-Fite BioPharma stock. Armistice Capital LLC grew its holdings in Can-Fite BioPharma Ltd. (NYSE:CANF – Free Report) by 35.5% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 518,853 shares of the company’s stock after acquiring an additional 136,055 shares during the quarter. Armistice Capital LLC owned 14.66% of Can-Fite BioPharma worth $1,339,000 as of its most recent SEC filing. 21.00% of the stock is owned by hedge funds and other institutional investors.

About Can-Fite BioPharma

(Get Free Report)

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.